Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncology Physicians who Treat CID (US)

Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Analysis of: Roche decision denies cancer drug to Britons (www.ft.com)
Roche has elected not to provide information on the cost effectiveness and clinical effectiveness of Avastin in breast cancer to the medicine advisory board of the British government.  As such, the drug will not be able for first line treatment of these diseases in Britain.
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells (content.nejm.org)
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
Analysis of: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer (content.nejm.org)
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
Analysis of: Roche decision denies cancer drug to Britons (www.ft.com)
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
Analysis of: Medicare fees to doctors fall Tuesday (news.yahoo.com)
Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??
Analysis of: Europe Backs Anemia-Drug Warnings (online.wsj.com)
Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.
Analysis of: Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty (content.nejm.org)
This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents (www.medscape.com)
Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.
Analysis of: Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer (jco.ascopubs.org)
Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next71 to 80 of 512

Analytics


Generated at 2009-01-07T19:00:58.307